MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 100947 | Name: Rucaparib free base
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rucaparib is a tricyclic indole poly(ADP-Ribose) polymerase (PARP1) inhibitor with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Rucaparib selectively binds to PARP1 and inhibits PARP1-mediated DNA repair, thereby enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis.

Chemical Structure

Rucaparib free base
Rucaparib free base
CAS#283173-50-2 (free base)

Theoretical Analysis

MedKoo Cat#: 100947

Name: Rucaparib free base

CAS#: 283173-50-2 (free base)

Chemical Formula: C19H18FN3O

Exact Mass: 323.1434

Molecular Weight: 323.37

Elemental Analysis: C, 70.57; H, 5.61; F, 5.88; N, 12.99; O, 4.95

Price and Availability

Size Price Availability Quantity
25mg USD 90.00 Ready to ship
50mg USD 150.00 Ready to ship
100mg USD 250.00 Ready to ship
200mg USD 450.00 Ready to ship
500mg USD 950.00 Ready to ship
1g USD 1,650.00 Ready to ship
2g USD 2,950.00 Ready to ship
5g USD 5,850.00 Ready to ship
10g USD 8,950.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
283173-50-2 (free base) 459868-92-9 (phosphate) 1859053-21-6 (camsylate)
Synonym
AG14699 (phosphate); AG 14699; AG-14699; AG014447 (as free base); AG-014447; AG 014447; PF01367338; PF-01367338; PF 01367338; Rucaparib free base, Rubraca.
IUPAC/Chemical Name
8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one
InChi Key
HMABYWSNWIZPAG-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)
SMILES Code
O=C1NCCC2=C(C3=CC=C(CNC)C=C3)NC4=C2C1=CC(F)=C4
Appearance
Yellow solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO (up to 20mg/mL)
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
Rucaparib (AG014699) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay.
In vitro activity:
The absorption, distribution, metabolism, elimination, and drug-drug interaction (DDI) potential of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib was characterised in vitro. Rucaparib showed moderate cellular permeability, moderate human plasma protein binding (70.2%), and slow metabolism in human liver microsomes (HLMs). In HLMs, cytochrome P450 (CYP) 1A2 and CYP3A contributed to the metabolism of rucaparib to its major metabolite M324 with estimated fractions of metabolism catalysed by CYP (fm,CYP) of 0.27 and 0.64, respectively. Rucaparib reversibly inhibited CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3As (IC50, 3.55, 12.9, 5.42, 41.6, and 17.2-22.9 µM [2 substrates], respectively), but not CYP2B6 or CYP2C8 (>190 µM). Reference: Xenobiotica. 2020 Sep;50(9):1032-1042. https://www.tandfonline.com/doi/abs/10.1080/00498254.2020.1737759?journalCode=ixen20
In vivo activity:
The effects of rucaparib on the proliferation of cervical cancer cells and sensitivity to radiotherapy were investigated. Animal experiments were performed to evaluate tumor size after treatment with rucaparib. Immunohistochemistry was performed to analyze the expression of Ki-67. Rucaparib suppressed proliferation, induced G2/M phase arrest, and reduced the expression of cyclin D1 and CDK4 in cervical cancer cells. When rucaparib was combined with radiotherapy in cervical cancer cells, clone formation decreased significantly and G2/M phase arrest was accentuated. The expression of the DNA-damage marker ץ-H2AX was increased significantly, and rucaparib suppressed tumor growth in vivo. Rucaparib exerts significant anti-proliferative effects and can serve as an effective radiosensitizer in cervical cancer. Reference: Invest New Drugs. 2019 Feb;37(1):65-75. https://link.springer.com/article/10.1007%2Fs10637-018-0616-7
Solvent mg/mL mM
Solubility
DMSO 46.7 144.32
Ethanol 16.5 51.03
DMF 30.0 92.77
DMF:PBS(pH 7.2)(1:1) 0.5 1.55
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 323.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Liao M, Jaw-Tsai S, Beltman J, Simmons AD, Harding TC, Xiao JJ. Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor. Xenobiotica. 2020 Sep;50(9):1032-1042. doi: 10.1080/00498254.2020.1737759. Epub 2020 Mar 18. PMID: 32129697. 2. Tang M, Liu Q, Zhou L, Chen L, Yang X, Yu J, Wang Y, Qiu H. The poly (ADP-ribose) polymerase inhibitor rucaparib suppresses proliferation and serves as an effective radiosensitizer in cervical cancer. Invest New Drugs. 2019 Feb;37(1):65-75. doi: 10.1007/s10637-018-0616-7. Epub 2018 Jun 6. PMID: 29872938.
In vitro protocol:
1. Liao M, Jaw-Tsai S, Beltman J, Simmons AD, Harding TC, Xiao JJ. Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor. Xenobiotica. 2020 Sep;50(9):1032-1042. doi: 10.1080/00498254.2020.1737759. Epub 2020 Mar 18. PMID: 32129697.
In vivo protocol:
1. Tang M, Liu Q, Zhou L, Chen L, Yang X, Yu J, Wang Y, Qiu H. The poly (ADP-ribose) polymerase inhibitor rucaparib suppresses proliferation and serves as an effective radiosensitizer in cervical cancer. Invest New Drugs. 2019 Feb;37(1):65-75. doi: 10.1007/s10637-018-0616-7. Epub 2018 Jun 6. PMID: 29872938.
1: Adrianto N, Mangkuliguna G, Tandiono EJ, Sibarani CNR. Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis. Taiwan J Obstet Gynecol. 2024 Sep;63(5):601-609. doi: 10.1016/j.tjog.2024.05.020. PMID: 39266137. 2: Houdou L, Rodrigues M. Rucaparib en monothérapie de maintenance chez les patientes atteintes d’un cancer de l’ovaire récemment diagnostiqué [Rucaparib in maintenance in patients with newly diagnosed ovarian cancer]. Bull Cancer. 2024 Sep 10:S0007-4551(24)00257-1. French. doi: 10.1016/j.bulcan.2024.05.011. Epub ahead of print. PMID: 39261252. 3: Gabriella M, Donato P, Maura C, Donatella R, Graziana R, Simona L, Vanda S, Aida DS, Vittoria B, Valeria E, Elisabetta P, Claudia M, Grazia DM, Eleonora P, Rosa A, Viola L, Roberta G, Raffaella R, Andrea RS, Savino C, Anna F, Antonietta GM, Giovanni S, Francesco D, Gabriella F. STEREOTACTIC BODY RADIOTHERAPY FOR OLIGOPROGRESSIVE OVARIAN CANCER PATIENTS TREATED DURING PARP INHIBITOR MAINTENANCE: EFFICACY AND ADVERSE EVENTS FROM THE EPIMETHEO RETROSPECTIVE STUDY. Int J Radiat Oncol Biol Phys. 2024 Sep 8:S0360-3016(24)03369-8. doi: 10.1016/j.ijrobp.2024.09.010. Epub ahead of print. PMID: 39255875. 4: Huang Y, He H, Liang L, Zhang Y, Peng K, Wang Y, Wu J, Long X, Kairemo K, Goldberg H, Mendez LC, Gu D. Efficacy and safety of PARP inhibitors in the treatment of prostatic cancer: a systematic review and network meta-analysis. Chin Clin Oncol. 2024 Aug;13(4):64. doi: 10.21037/cco-24-82. PMID: 39238347. 5: Papp H, Tóth E, Bóvári-Biri J, Bánfai K, Juhász P, Mahdi M, Russo LC, Bajusz D, Sipos A, Petri L, Szalai TV, Kemény Á, Madai M, Kuczmog A, Batta G, Mózner O, Vaskó D, Hirsch E, Bohus P, Méhes G, Tőzsér J, Curtin NJ, Helyes Z, Tóth A, Hoch NC, Jakab F, Keserű GM, Pongrácz JE, Bai P. The PARP inhibitor rucaparib blocks SARS-CoV-2 virus binding to cells and the immune reaction in models of COVID-19. Br J Pharmacol. 2024 Aug 27. doi: 10.1111/bph.17305. Epub ahead of print. PMID: 39191429. 6: Jin W, Zhang Z, Sun W, Li J, Xiong W. Neurological toxicities with poly (ADP- ribose) polymerase inhibitors in cancer patients: a systematic review and meta- analysis. J Chemother. 2024 Aug 23:1-15. doi: 10.1080/1120009X.2024.2392463. Epub ahead of print. PMID: 39180239. 7: Xiao F, Wang Z, Qiao L, Zhang X, Wu N, Wang J, Yu X. Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer. J Transl Med. 2024 Aug 21;22(1):778. doi: 10.1186/s12967-024-05583-z. PMID: 39169400; PMCID: PMC11337781. 8: Lin X, Soni A, Hessenow R, Sun Y, Mladenov E, Guberina M, Stuschke M, Iliakis G. Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Polθ inhibition. Radiother Oncol. 2024 Aug 13;200:110475. doi: 10.1016/j.radonc.2024.110475. Epub ahead of print. PMID: 39147034. 9: McCormick A, Donoghue P, Dixon M, O'Sullivan R, O'Donnell RL, Murray J, Kaufmann A, Curtin NJ, Edmondson RJ. Correction: Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib. Clin Cancer Res. 2024 Aug 15;30(16):3640. doi: 10.1158/1078-0432.CCR-24-2051. Erratum for: Clin Cancer Res. 2017 Apr 15;23(8):2050-2060. doi: 10.1158/1078-0432.CCR-16-0564. PMID: 39143885. 10: Kulkarni S, Gajjar K, Madhusudan S. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer. Front Oncol. 2024 Jul 29;14:1414112. doi: 10.3389/fonc.2024.1414112. PMID: 39135999; PMCID: PMC11317305. 11: Yang C, Song X, Sun H, Chen X, Liu C, Chen M. Cardiovascular adverse events associated with PARP inhibitors for ovarian cancer: a real world study (RWS) with Bayesian disproportional analysis based on the FDA adverse event reporting system (FAERS). Expert Opin Drug Saf. 2024 Aug 12:1-8. doi: 10.1080/14740338.2024.2390640. Epub ahead of print. PMID: 39132853. 12: Rose PG. Prolonged treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing. Gynecol Oncol Rep. 2024 Jul 11;54:101458. doi: 10.1016/j.gore.2024.101458. PMID: 39082050; PMCID: PMC11287010. 13: Rauch H, Kitzberger C, Janghu K, Hawarihewa P, Nguyen NT, Min Y, Ballke S, Steiger K, Weber WA, Kossatz S. Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2024 Jul 18. doi: 10.1007/s00259-024-06844-1. Epub ahead of print. PMID: 39023784. 14: Pierre ME, Manneh R, Hernández A, Rodríguez J, Fletcher AV, Ramírez HM, Niño OM, Gómez DA, Sanabria D, Contreras F, Pieschacón JR, Calderón PH. Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer. Rev Colomb Obstet Ginecol. 2024 Jun 14;75(1):4094. English, Spanish. doi: 10.18597/rcog.4094. PMID: 39013199; PMCID: PMC11210286. 15: He C, Shi H, Tan B, Jiang Z, Cao R, Zhu J, Qian K, Wang X, Xu X, Qu C, Song S, Cheng Z. Quinazoline-2,4(1 H,3 H)-dione Scaffold for development of a novel PARP-targeting PET probe for tumor imaging. Eur J Nucl Med Mol Imaging. 2024 Jul 16. doi: 10.1007/s00259-024-06843-2. Epub ahead of print. PMID: 39012502. 16: Schwarcz S, Nyerges P, Bíró TI, Janka E, Bai P, Mikó E. Cytostatic Bacterial Metabolites Interfere with 5-Fluorouracil, Doxorubicin and Paclitaxel Efficiency in 4T1 Breast Cancer Cells. Molecules. 2024 Jun 27;29(13):3073. doi: 10.3390/molecules29133073. PMID: 38999024; PMCID: PMC11243325. 17: Crabb SJ, Khalid T, Woods L, Frampton G, Shepherd J. PARP Inhibitors for Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy and Safety. Bladder Cancer. 2023 Dec 13;9(4):365-376. doi: 10.3233/BLC-230071. PMID: 38994249; PMCID: PMC11165942. 18: Kristeleit R, Leary A, Oaknin A, Redondo A, George A, Chui S, Seiller A, Liste-Hermoso M, Willis J, Shemesh CS, Xiao J, Lin KK, Molinero L, Guan Y, Ray- Coquard I, Mileshkin L. PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers. Br J Cancer. 2024 Sep;131(5):820-831. doi: 10.1038/s41416-024-02776-7. Epub 2024 Jul 6. PMID: 38971950; PMCID: PMC11369183. 19: Ren X, Sun P, Wang Y. PARP inhibitor-related acute renal failure: a real- world study based on the FDA adverse event reporting system database. Expert Opin Drug Saf. 2024 Jul 8:1-9. doi: 10.1080/14740338.2024.2376690. Epub ahead of print. PMID: 38967020. 20: Smith HL, Willmore E, Prendergast L, Curtin NJ. ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors. Br J Cancer. 2024 Sep;131(5):905-917. doi: 10.1038/s41416-024-02745-0. Epub 2024 Jul 4. PMID: 38965423; PMCID: PMC11369084.

View History

BW 175

BW 175